BenevolentAI vs Kepler Vision

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. BenevolentAI employs 100-500 people, while Kepler Vision has 1-50 employees.

BenevolentAI has raised $292M in disclosed funding across 0 known rounds. Kepler Vision's funding history is not publicly available.

BenevolentAI holds the higher Awaira Score at 62/100, compared to Kepler Vision's 30/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 32-point gap that reflects meaningful differences in scale or traction.

BenevolentAI was founded by Joanna Shields in 2013. Kepler Vision was founded by Harro Stokman in 2017. Visit each company's profile on Awaira for a full founder biography.

BenevolentAI: BenevolentAI applies machine learning to drug discovery, using knowledge graph technology and predictive AI models to identify novel drug candidates and repurpose existing compounds for new therapeutic applications. The London-based company has built a proprietary biomedical knowledge graph containing billions of data points extracted from scientific literature, clinical trial data, and genomic databases, which feeds its target identification and molecule generation pipelines.\n\nThe company went public on Euronext Amsterdam in 2022 via a SPAC merger with Odyssey Acquisition, having previously raised approximately $292 million in private funding from backers including SoftBank, Woodford Investment Management, and Mayfair Equity Partners. BenevolentAI has clinical-stage programs in atopic dermatitis and amyotrophic lateral sclerosis, developed from AI-generated hypotheses that were subsequently validated in wet lab experiments and progressed into human trials.\n\nBenevolentAI operates in the AI drug discovery sector alongside Recursion Pharmaceuticals, Exscientia, and Insilico Medicine. The company faces the inherent challenge of all computational drug discovery platforms in demonstrating that AI-generated candidates can survive clinical attrition at higher rates than traditionally discovered drugs. The platform is considered one of the more mature AI drug discovery systems in Europe, with the longest track record of moving AI-generated hypotheses into clinical development. Kepler Vision: Kepler Vision Technologies develops AI fall detection and activity recognition software for elderly care environments, using computer vision models that process video from ceiling-mounted cameras in care facilities to detect falls, assess resident activity patterns, and alert care staff to incidents requiring immediate response. The Amsterdam company platform is designed to operate without wearables or pressure sensors, relying entirely on camera-based analysis to provide unobtrusive monitoring.\n\nThe company is early stage with initial funding from Dutch innovation programmes and care sector partners. Kepler Vision has piloted its Night Nurse product in Dutch residential care facilities, where staff shortages create demand for AI monitoring tools that can maintain safety oversight overnight when staffing ratios are lowest. The platform is designed to comply with European privacy regulations governing personal data processing in care environments, using on-device processing to avoid transmitting identifiable video to cloud services.\n\nKepler Vision operates in the AI elder care market alongside CarePredict, SafelyYou, and camera-based monitoring startups targeting the intersection of computer vision and residential care. The European elder care AI market faces distinct regulatory challenges compared to the US, with GDPR-compliant video monitoring in care facilities requiring explicit consent frameworks and data minimisation approaches. The Netherlands position as a leader in healthcare technology innovation and its advanced residential care infrastructure make it a relevant test market for technology that addresses the growing caregiver shortage across European social care systems.

BenevolentAI was founded first in 2013, giving it 4 years of additional market experience. Kepler Vision was founded later in 2017. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

BenevolentAI has approximately 100-500 employees, while Kepler Vision has approximately 1-50. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, BenevolentAI and Kepler Vision are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.